REMoxTB trial results confirm moxifloxacin safety but not shortened tuberculosis treatment
The results of REMoxTB, a phase III global clinical trial of new tuberculosis drug regimens, were presented Sunday 7 September 2014 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy and published in the New England Journal of Medicine. The trial was led by Prof. Stephen H. Gillespie (St. Andrews University, Scotland) and conducted mainly in Africa (approximately 70% of patients).
The sponsor of the trial, the TB Alliance, stated in its press release that replacing one of the drugs in the standard six-month treatment regimen with moxifloxacin “did not allow the treatment time for tuberculosis (TB) patients to be shortened to four months”. “While the experimental regimens initially killed more TB bacteria than the standard regimen, patients receiving those shortened regimens were more likely to relapse than those taking the standard treatment.”